Ribavirin does not potentiate favipiravir antiviral activity against Ebola virus in non-human primates
- 2 March 2020
- journal article
- research article
- Published by Elsevier BV in Antiviral Research
- Vol. 177, 104758
- https://doi.org/10.1016/j.antiviral.2020.104758
Abstract
No abstract availableKeywords
Funding Information
- Horizon 2020
This publication has 31 references indexed in Scilit:
- Population Pharmacokinetics and Pharmacodynamics of Ribavirin in Patients with Chronic Hepatitis C Genotype 1 InfectionThe AAPS Journal, 2012
- Depletion of GTP pool is not the predominant mechanism by which ribavirin exerts its antiviral effect on Lassa virusAntiviral Research, 2011
- Review of the Literature and Proposed Guidelines for the Use of Oral Ribavirin as Postexposure Prophylaxis for Lassa FeverClinical Infectious Diseases, 2010
- Ribavirin Antagonizes the In Vitro Anti-Hepatitis C Virus Activity of 2′- C -Methylcytidine, the Active Component of ValopicitabineAntimicrobial Agents and Chemotherapy, 2006
- Mechanism of Action of T-705 against Influenza VirusAntimicrobial Agents and Chemotherapy, 2005
- Metabolism and antiviral activity of ribavirinVirus Research, 2005
- Pharmacokinetics and Metabolism of [14C]Ribavirin in Rats and Cynomolgus MonkeysAntimicrobial Agents and Chemotherapy, 2003
- Ribavirin Quantification in Combination Treatment of Chronic Hepatitis CAntimicrobial Agents and Chemotherapy, 2003
- Hematological and bone marrow effects of ribavirin in rhesus monkeysToxicology and Applied Pharmacology, 1984
- Enhanced Treatment of Lassa Fever by Immune Plasma Combined with Ribavirin in Cynomolgus MonkeysThe Journal of Infectious Diseases, 1984